Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 19/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MT-CO1 | P00395 | 1/20 | 0.70 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dup-697 SCHEMBL1041241 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL10567845 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL9206986 | 0.80 | PTGS2 (0.73) | PTGS2PTGS1SCDFADS1 | |
| SCHEMBL8985377 | 0.78 | PTGS2 (0.46) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985314 | 0.77 | PTGS2 (0.75) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985413 | 0.75 | PTGS2 (0.71) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985340 | 0.74 | PTGS2 (0.70) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL8985295 | 0.72 | PTGS2 (0.67) | PTGS2PTGS1KDM4EMT-CO1MT-CO2 | |
| SCHEMBL7087907 | 0.72 | PTGS2 (0.61) | PTGS2PTGS1SCDFADS1 | |
| SCHEMBL6732658 | 0.71 | PTGS2 (0.70) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0821589-B1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NITROMED INC (US) | 2009-02-04 | — | — | EP | claimed |
| US-20030109520-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NICOX S.A. (FR) | 2003-06-12 | — | — | US | claimed |
| EP-0821589-A4 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NITROMED INC (US) | 2002-05-15 | — | — | EP | claimed |
| US-6057347-A | COMPRISING NONSTEROIDAL ANTIINFLAMMATORY DRUG AND COMPOUND THAT DONATES, TRANSFERS, OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS SYNTHESIS LEVELS OF NITRIC OXIDE, OR IS SUBSTRATE FOR NITRIC OXIDE SYNTHASE | NITROMED, INC. (US) | 2000-05-02 | — | — | US | claimed |
| EP-0821589-A1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Nitromed, Inc. (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996032946-A1 | COMPOSITIONS AND METHODS TO PREVENT TOXICITY INDUCED BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NITROMED, INC. (US) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109520-A1 | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs | NOS2, NOS3, MB | PTGS2 6/4885PTGS1 5/4885KDM4E 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.